HOW TO SEE IF AI CAN BE TRUSTED IN R&D DECISIONS | BIOTECHX - JOHN WILEY & SONS INC

Based on the provided transcript, there are no financial market guidance, revenue/earnings outlooks, capital allocation plans, or macroeconomic forecasts available. The speaker (Armaghan Rafat) presents a product launch and a conceptual framework for AI verification rather than a corporate financial earnings report.

Consequently, the following sections of your requested template contain no reportable data from this specific text:

• Explicit Guidance: None. No revenue, earnings, margins, capex, or share count guidance for FY2024, FY2025, or beyond is mentioned.
• Business-Segment Outlook: None. While the speaker discusses the "Applied Research Intelligence" (ARRI) platform, there are no specific targets for user acquisition, revenue contribution of this product line, or market share expansion timelines.
• Market and Competitive Outlook: None. No specific forecasts on demand trends, pricing strategies, or competitive share shifts are provided, other than the observation that "frontier models are cheap" and currently suffer from "opacity."
• Macro / Industry Outlook: None. No commentary on interest rates, inflation, FX, or regulatory tax changes is offered.
• Strategic Initiatives:
  • Launching the Wiley Applied Research Intelligence (ARRI) platform as a beta capability in Basel.
  • Implementation of a patent-pending capability called "playbooks" to allow workflow customization without prompting.
  • Feature rollout: Weekly automatic refreshing of research landscapes and workspaces.
• Risks and Headwinds to Outlook: None. No specific risks to the beta launch or the company's financial outlook are detailed.
• Management Tone on the Future:
  • Confidence: High confidence in the necessity of "verifiable proof" over "confident voices" in AI.
  • Philosophy: Emphasizes that "trust is a product" defined by the ability to "check" and "defend" decisions, rather than blind faith.
  • Call to Action: Invites users to test the product ("run those three tests on us") to validate efficacy, rather than accepting claims on authority.
• Miscellaneous:
  • Market Data Trend: Peer-reviewed research papers are published at a rate of one every 10 seconds; reference lists have tripled in size over the past decade.
  • Adoption Statistics: AI usage among researchers rose from 57% (last year) to 84% (this year); AI hallucination concerns rose by 13 percentage points.
  • Industry Pain Points: 9 out of 10 drugs entering human trials fail approval; successful drugs cost $1.7B–$2.6B to develop.
  • Problem Identification: 1 in 277 papers (up from 1 in 3,000 three years ago) contained invalid links in PubMed, highlighting the risk of unverified data.